Payment overview · 2025
General Payments
$218.05
12 reported records · 7 companies
Healthcare provider profile · identity verified
Gary D Gray, MD
Allopathic & Osteopathic Physicians|Internal Medicine · O FALLON, MO · NPI 1497729826
Verified facts
What the public records show
CMS Open Payments records show Gary D Gray, MD received $218.05 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Arexvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.14 | 27.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.67 | 23.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.46 | 18.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.26 | 9.8% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $17.44 | 8.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.23 | 7.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.85 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $218.05 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.77 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $37.49 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.08 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 113 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 139 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 186 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
113 | 113 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
186 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
139 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 577 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 449 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 376 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 357 | 107 |
| Losartan Potassium | Losartan Potassium | 339 | 91 |
| Lisinopril | Lisinopril | 336 | 88 |
| Metformin Hcl | Metformin Hcl | 325 | 91 |
| Alprazolam | Alprazolam | 316 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 275 | 81 |
| Fluoxetine Hcl | Fluoxetine Hcl | 254 | 74 |
| Trazodone Hcl | Trazodone Hcl | 252 | 63 |
| Pravastatin Sodium | Pravastatin Sodium | 247 | 64 |
| Simvastatin | Simvastatin | 235 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 204 | 31 |
| Omeprazole | Omeprazole | 203 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 55 |
| Azithromycin | Azithromycin | 190 | 137 |
| Ozempic | Semaglutide | 186 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 42 |
| Sertraline Hcl | Sertraline Hcl | 176 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 169 | 56 |
| Gabapentin | Gabapentin | 167 | 50 |
| Potassium Chloride | Potassium Chloride | 165 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 50 |
| Bupropion Xl | Bupropion Hcl | 159 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 33 |
| Furosemide | Furosemide | 144 | 44 |
| Tramadol Hcl | Tramadol Hcl | 142 | 43 |
| Eliquis | Apixaban | 139 | 31 |
| Prednisone | Prednisone | 138 | 74 |
| Allopurinol | Allopurinol | 135 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 44 |
| Methylprednisolone | Methylprednisolone | 123 | 98 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 113 | 113 |
| Meloxicam | Meloxicam | 111 | 39 |
| Metformin Hcl Er | Metformin Hcl | 108 | 30 |
| Atenolol | Atenolol | 107 | 31 |
| Glimepiride | Glimepiride | 99 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 22 |
| Lorazepam | Lorazepam | 79 | 21 |
| Famotidine | Famotidine | 78 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 78 | 22 |
| Carvedilol | Carvedilol | 77 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | 16 |
| Valacyclovir | Valacyclovir Hcl | 62 | 25 |
| Montelukast Sodium | Montelukast Sodium | 61 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 15 |
| Clonazepam | Clonazepam | 58 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 36 |
| Jardiance | Empagliflozin | 56 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 12 |
| Mirtazapine | Mirtazapine | 52 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 15 |
| Finasteride | Finasteride | 51 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Ezetimibe | Ezetimibe | 43 | 11 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Lovastatin | Lovastatin | 40 | 11 |
| Clonidine Hcl | Clonidine Hcl | 38 | 15 |
| Cefdinir | Cefdinir | 36 | 29 |
| Cefuroxime | Cefuroxime Axetil | 36 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 14 |
| Donepezil Hcl | Donepezil Hcl | 35 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 12 |
| Spironolactone | Spironolactone | 35 | 11 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 22 |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 11 |
| Telmisartan | Telmisartan | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 20 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 16 |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 18 |
| Mupirocin | Mupirocin | 23 | 19 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Acyclovir | Acyclovir | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Klor-Con M10 | Potassium Chloride | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Metaxalone | Metaxalone | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Misoprostol | Misoprostol | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $218.05 · 12 records | Novo Nordisk Inc | ABRYSVO, AREXVY, COMIRNATY, ELIQUIS, JARDIANCE, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, SHINGRIX, Senza, Wegovy, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error